Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2009

View Archived Issues

Bristol-Myers and ZymoGenetics sign collaboration for PEG-Interferon lambda in hepatitis C

FORMA and Novartis enter collaboration to develop inhibitors of protein-protein interactions

Cobalis to launch antiallergic drug PreHistin in February 2009

Boehringer Ingelheim divulges novel protein kinase inhibitors for use in treating cancer

Mochida and Shire sign Japanese license agreement for Lialda for ulcerative colitis

Daiichi Sankyo to make an open offer for acquisition of 20% of Zenotech common stock

FDA unable to complete review of Takeda's NDA for febuxostat by January 2009

CSL Behring receives FDA approval of RiaSTAP for acute bleeding episodes

Intercell signs exclusive agreement with Novartis for Japanese encephalitis vaccine

Pfizer receives FDA complete response letter for lasofoxifene in osteoporosis

Novel Jak kinase inhibitors in early development at Novartis

New ERK2 inhibitors with oncolytic activity reported in recent Schering-Plough patent

AstraZeneca imparts novel metabotropic glutamate receptor oxadiazole ligands

Muscarinic M3 receptor ligands and beta2-adrenoceptor agonists imparted by Argenta and AstraZeneca

CRTH2 inhibitor from Actimis active in model of allergic skin inflammation

Normal and partially transformed human embryonic stem cells differentiated

Patients with advanced gastrointestinal carcinoid tumors respond well to AMG-479

Combination of AMG-655 and gemcitabine investigated in pancreatic cancer

Brivanib plus cetuximab more effective in K-ras wild-type colorectal cancer patients

Alzheimer's Drug Discovery Foundation provides grant to Edunn Biotechnology

MMRC and Merck & Co. initiate phase II Zolinza trial in multiple myeloma

UMN confirms immunogenicity and safety of UMN-0501 influenza vaccine

Hawaii Biotech completes dosing in phase I clinical trial of West Nile vaccine

ReNeuron receives U.K. approval for ground-breaking clinical trial of ReN-001 in ischemic stroke

Janssen Pharma launches HIV drug Intelence in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...